Emodin / COX2 Cancer Research Results

EMD, Emodin: Click to Expand ⟱
Features:
Organic compound isolated from rhubarb, buckthorn, knotweed. It has laxative, anticancer, antibacterial, antiinflammatory, and antiviral activities, and is used in traditional Chinese medicine.
Emodin, an anthraquinone derivative found in various plants (e.g., rhubarb, Polygonum cuspidatum).

Pathways:
- Generation of Reactive Oxygen Species (ROS)
- Upregulation Bax downregulation of Bcl‑2, caspase activation and cyt_c release.
- Induce cell cycle arrest at various checkpoints (commonly G0/G1 or G2/M phases.
- Can inhibit NF‑κB activation
– MAPK Pathways
– PI3K/Akt Pathway
- Metalloproteinases (MMPs)

-ic50 cancer cells 10-50uM, normal cells higher(supports a therapeutic window)

Rhubarb species Common name Plant part analyzed Emodin content Aloe-emodin content Interpretation
Rheum palmatum Chinese rhubarb Dried root and rhizome Approximately 1.1–2.0 mg/g Approximately 0.65–1.0 mg/g Major medicinal source; concentrations vary considerably with origin, plant age, processing, and extraction method.
Rheum officinale Medicinal rhubarb Dried root and rhizome Usually approximately 0.5–2 mg/g Usually approximately 0.5–2 mg/g Composition broadly resembles R. palmatum; some samples contain more aloe-emodin than emodin.
Rheum tanguticum Tangut rhubarb Root and rhizome; smaller amounts occur in aerial tissues Moderate to high; commonly approximately 1–3 mg/g in underground tissues Moderate; commonly below emodin One of the three principal Chinese medicinal rhubarb species. Tissue distribution differs, and some aerial tissues may contain appreciable emodin.
Rheum australe
syn. Rheum emodi		 Himalayan or Indian rhubarb Root and rhizome Present and frequently a major anthraquinone Present, generally lower and more variable Reported concentrations vary widely among wild populations; quantitative results are not directly comparable across extraction methods.
Rheum rhabarbarum / Rheum × hybridum Garden or culinary rhubarb Root and rhizome; edible petiole contains much less Low to moderate in roots; usually trace or low in petioles Low or trace in petioles; variable in roots Edible stalks are not compositionally equivalent to medicinal rhubarb roots. Most anthraquinones occur in underground tissues.

In rhubarb, the medicinal material described as “root and rhizome” includes both the true roots and the thick underground stem base from which the leaf stalks emerge.



Emodin — Emodin is a naturally occurring hydroxyanthraquinone and plant secondary metabolite, chemically identified as 1,3,8-trihydroxy-6-methylanthraquinone. It is a small-molecule natural product rather than an approved anticancer drug. Major sources include rhubarb species, Japanese knotweed, buckthorn, Polygonum multiflorum, Polygonum cuspidatum, Rheum palmatum, and several fungi. Emodin is pharmacologically pleiotropic, with redox-active, kinase-modulating, anti-inflammatory, cytotoxic, laxative, and antimicrobial properties. Its anticancer effects remain predominantly preclinical, and emodin should be distinguished from the related compounds aloe-emodin and rhein.

Primary mechanisms (ranked):

  1. Induction of oxidative stress and mitochondrial dysfunction, producing ROS accumulation, mitochondrial membrane depolarization, cytochrome-c release, and caspase-dependent apoptosis.
  2. Suppression of PI3K/AKT/mTOR and related survival signaling, frequently accompanied by AMPK activation, reduced protein synthesis, metabolic stress, and apoptosis.
  3. Modulation of BAX/BCL-2-family proteins and activation of intrinsic and, in some models, extrinsic apoptotic pathways.
  4. Cell-cycle arrest through context-dependent modulation of p53, p21, ATM, cyclins, CDKs, and checkpoint proteins.
  5. Inhibition of NF-κB, STAT3, TLR4, JAK, MAPK, HER2, CK2, and other pro-survival or inflammatory signaling pathways.
  6. Suppression of glycolysis and anabolic metabolism through reduced GLUT1, HK2, PKM2, LDHA, FASN, and AKT/mTOR activity in selected cancer models.
  7. Inhibition of invasion, epithelial–mesenchymal transition, angiogenesis, and cancer-stem-cell phenotypes through reduced MMPs, HIF-1α, VEGF, TGF-β, CXCR4, and mesenchymal signaling.
  8. Induction of autophagy, ER stress, DNA-damage responses, or necroptosis in model-dependent settings.
  9. NRF2/HO-1 activation as a secondary, context-dependent antioxidant response that may protect normal cells but can also oppose emodin-induced cytotoxic oxidative stress.
  10. Chemosensitization through inhibition of survival, resistance, stemness, cholesterol-metabolism, or drug-efflux pathways; the interaction is drug- and tumor-dependent.

Bioavailability / PK relevance: Native emodin has very poor oral bioavailability, estimated at approximately 3% in rat studies. It has low aqueous solubility, incomplete intestinal absorption, extensive intestinal and hepatic glucuronidation and sulfation, and rapid systemic clearance. Circulating exposure is therefore dominated by conjugated metabolites rather than sustained concentrations of free emodin. Nanoparticles, liposomes, phospholipid complexes, prodrugs, and other delivery systems are being investigated but are not established clinical formulations.

In-vitro vs systemic exposure relevance: Most anticancer experiments use approximately 10–100 µM emodin, commonly 20–50 µM. These free-drug concentrations are unlikely to be maintained systemically after conventional oral administration because of poor absorption and rapid conjugation. In-vitro findings therefore substantially overstate the exposure achievable with unformulated oral emodin. Local gastrointestinal exposure may be higher, but this does not establish therapeutically useful tumor exposure.

Clinical evidence status: Preclinical. Evidence consists primarily of cancer-cell studies and rodent xenograft or chemically induced tumor models. Emodin has shown experimental adjunct and chemosensitizing effects with agents including paclitaxel, sorafenib, cisplatin, gemcitabine, and other therapies, but there is no established randomized clinical evidence supporting emodin as a cancer treatment. Emodin is not an FDA-, EMA-, or Health Canada-approved anticancer agent.

Safety: Emodin is not necessarily tumor-selective and can produce ROS, mitochondrial injury, apoptosis, and genotoxic signals in nonmalignant cells at sufficient concentrations. Preclinical literature reports possible hepatotoxicity, nephrotoxicity, reproductive toxicity, gastrointestinal irritation, laxative effects, and complex mutagenicity findings, particularly with high doses or prolonged exposure. It may also affect CYP enzymes, conjugating enzymes, transporters, and the pharmacokinetics of co-administered drugs. Long-term concentrated supplementation should not be considered equivalent to ordinary dietary exposure from rhubarb or other foods.


Mechanistic Profile of Emodin

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 ROS-driven mitochondrial injury ↑ ROS
↓ mitochondrial membrane potential
↓ ATP		 ↑ ROS and mitochondrial injury at cytotoxic exposure P–R Upstream cytotoxic stress A central mechanism in many cancer models, but not intrinsically cancer-specific. Redox outcome varies with dose, cell type, antioxidant capacity, and exposure duration.
2 Intrinsic mitochondrial apoptosis ↑ BAX
↓ BCL-2 and BCL-XL
↑ cytochrome-c
↑ caspase-9 and caspase-3
↑ PARP cleavage		 ↑ apoptosis at high concentration or prolonged exposure R–G Programmed cell death Frequently follows ROS accumulation and mitochondrial depolarization. Extrinsic Fas and caspase-8 signaling also contributes in some models.
3 PI3K AKT mTOR and AMPK signaling ↓ PI3K
↓ AKT
↓ mTOR
↑ AMPK (context-dependent)		 Mixed or tissue-protective modulation (context-dependent) R–G Reduced survival and anabolic signaling Mechanistically important across several tumor types, although AMPK activation is not universal and may differ by metabolic state.
4 Cell-cycle checkpoints and DNA-damage response ↑ ATM
↑ p53
↑ p21
↓ cyclin D1, cyclin E, or cyclin B1
↓ CDK activity		 Cell-cycle disturbance possible at cytotoxic exposure G G0/G1, S-phase, or G2/M arrest The arrest point is cell-line and dose-dependent. Emodin should not be assigned to one universal checkpoint.
5 NF-κB TLR4 inflammatory survival signaling ↓ TLR4
↓ IKK activation
↓ IκBα degradation
↓ NF-κB nuclear activity		 ↓ inflammatory signaling in many injury models R–G Reduced survival, inflammation, and treatment resistance This axis contributes to both anticancer and anti-inflammatory effects and may reduce cytokine-driven tumor support.
6 JAK STAT3 and receptor kinase signaling ↓ JAK1 and JAK2
↓ STAT3
↓ HER2
↓ CK2 or Src signaling (model-dependent)		 Mixed; possible inhibition of physiological kinase signaling R–G Reduced proliferation and anti-apoptotic transcription Direct and indirect kinase effects have been reported, but target dominance varies substantially among tumor models.
7 Glycolysis and metabolic dependency ↓ GLUT1
↓ HK2
↓ PKM2
↓ LDHA
↓ ECAR
↓ glycolysis		 PKM2 and metabolic modulation reported (context-dependent) R–G Energy stress and reduced biosynthetic capacity Prominent in selected renal and hepatic cancer models but not yet established as a universal primary mechanism.
8 HIF-1α VEGF angiogenic program ↓ HIF-1α biosynthesis
↓ VEGF
↓ angiogenesis		 Potential impairment of physiological hypoxic adaptation at sufficient exposure G Reduced hypoxia tolerance and vascular support Evidence includes reduced HIF-1α protein synthesis rather than exclusively altered transcription or degradation.
9 EMT invasion and extracellular-matrix remodeling ↑ E-cadherin
↓ N-cadherin
↓ vimentin
↓ MMP2 and MMP9
↓ TGF-β signaling		 Possible modulation of wound repair and fibrosis pathways G Reduced migration, invasion, and metastatic phenotype Effects may involve tumor cells, macrophages, stromal signaling, and cancer-stem-cell maintenance.
10 Cancer stemness and differentiation state ↓ CD133
↓ OCT4
↓ NOTCH1
↓ stem-cell formation		 Effects on normal progenitor populations are insufficiently characterized G Reduced tumor initiation and recurrence-associated phenotype Supported primarily by cell and animal models; clinically meaningful selectivity has not been established.
11 Autophagy ER stress and necroptosis ↑ autophagy
↑ ER stress or ↓ ER stress (model-dependent)
↑ RIP1 and MLKL signaling in selected models		 Protective or toxic depending on tissue and exposure R–G Alternative stress-response and death pathways Autophagy can facilitate death or survival. Necroptosis has been demonstrated in selected renal cancer models but should not be generalized.
12 NRF2 HO-1 antioxidant response ↑ NRF2
↑ HO-1 (secondary; context-dependent)		 ↑ NRF2-mediated antioxidant and cytoprotective signaling R–G Compensatory antioxidant response NRF2 activation may limit oxidative injury in normal tissues but could also reduce emodin cytotoxicity or support resistant cancer cells. It is not consistently the primary anticancer mechanism.
13 HDAC and chromatin regulation ↓ HDAC activity
↑ histone acetylation		 Epigenetic modulation possible R–G Altered transcriptional state Biochemical HDAC inhibition is reported, but the free concentrations required and its contribution in vivo remain uncertain.
14 Chemosensitization ↑ chemotherapy sensitivity
↓ survival and resistance pathways		 Potential ↑ normal-tissue toxicity or altered drug disposition G Enhanced response to selected anticancer agents Reported combinations are promising preclinically, but interactions cannot be assumed beneficial because emodin also affects metabolism, transport, redox balance, and normal-cell viability.
15 Clinical Translation Constraint ↓ free systemic exposure
↑ conjugated metabolites
heterogeneous tumor response		 Dose-limiting gastrointestinal and organ toxicity concerns G Limited translation of in-vitro activity Approximately 3% oral bioavailability in rat studies, extensive glucuronidation and sulfation, poor solubility, short exposure, absence of validated clinical dosing, and lack of randomized oncology trials are major limitations.

P: 0–30 min    R: 30 min–3 hr    G: >3 hr
COX2, cycloocygenase-2 (Cox-2) mRNA and Cox-2 protein: Click to Expand ⟱
Source: HalifaxProj(inhibit)
Type:
Cyclooxygenase-2 (COX-2) is an enzyme that plays a critical role in the conversion of arachidonic acid to prostaglandins, which are lipid compounds involved in various physiological processes, including inflammation, pain, and fever. COX-2 is an inducible enzyme, meaning its expression is typically low in normal tissues but can be upregulated in response to inflammatory stimuli, growth factors, and certain oncogenic signals.
-Cyclooxygenase-2 (COX-2), the rate-limiting enzyme in prostaglandin biosynthesis, plays a key role in inflammation and circulatory homeostasis.
-COX-2 is an inducible enzyme that is upregulated in response to pro-inflammatory signals, including cytokines (e.g., IL-1β, TNF-α) and growth factors.

COX-2 is often overexpressed in various tumors, including colorectal, breast, lung, and prostate cancers.
The prostaglandins produced by COX-2, particularly prostaglandin E2 (PGE2), have several effects that can facilitate cancer progression:
Cell Proliferation: PGE2 can promote the proliferation of cancer cells by activating signaling pathways such as the PI3K/Akt and MAPK pathways.
Nonselective NSAIDs, such as aspirin and ibuprofen, inhibit both COX-1 and COX-2. Epidemiological studies have suggested that regular use of NSAIDs may reduce the risk of certain cancers, particularly colorectal cancer.
Drugs specifically targeting COX-2, such as celecoxib, have been developed.

COX-2 and xanthine oxidase are ROS-producing pro-oxidant enzymes that contribute to inflammation. Elevated COX‑2 levels, often found in inflammatory conditions or certain types of cancers, can contribute to increased production of ROS.
Scientific Papers found: Click to Expand⟱
6820- EMD,    The Health Benefits of Emodin, a Natural Anthraquinone Derived from Rhubarb—A Summary Update
- Review, Nor, NA - Review, Arthritis, NA - Review, AD, NA
*diuretic↑, *Bacteria↓, *Inflam↓, AntiCan↑, TumCP↓, TumCI↓, angioG↓, *toxicity↓, IFN-γ↑, IL12↑, ROS↑, TNF-α↓, TNF-α↓, TGF-β↓, MAPK↓, PKCδ↓, NF-kB↓, HER2/EBBR2↓, VEGF↓, DNAdam↑, Necroptosis↑, Glycolysis↓, GLUT1↓, PI3K↓, Akt↓, Casp9↑, Casp3↑, BAX↑, Bcl-2↓, eff↑, MMP2↓, MMP9↓, eff↑, ChemoSen↑, P-gp↓, SREBP2↓, eff↑, *other↝, *COX2↓, *Hif1a↓, *HDAC↓, *tau↓, *PKCδ↑, *ROS↓, *Inflam↓, AntiAg?,
6827- EMD,    Mechanism of Emodin in the Treatment of Rheumatoid Arthritis
- Review, Arthritis, NA
*ALAT↓, *AST↓, *ROS↓, *cardioP↑, *TNF-α↓, *NF-kB↓, *Inflam↓, *AntiArt↑, *PGE2↓, *MMP3↓, *MMP13↓, *COX2↓, *AntiCan↑, *neuroP↑, *hepatoP↑,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ROS↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

Glycolysis↓, 1,   SREBP2↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 1,   Casp9↑, 1,   MAPK↓, 1,   Necroptosis↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

HER2/EBBR2↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

PI3K↓, 1,  

Migration(tgid=13) ⓘ

AntiAg?, 1,   MMP2↓, 1,   MMP9↓, 1,   PKCδ↓, 1,   TGF-β↓, 1,   TumCI↓, 1,   TumCP↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   VEGF↓, 1,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IFN-γ↑, 1,   IL12↑, 1,   NF-kB↓, 1,   TNF-α↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,   eff↑, 3,  

Clinical Biomarkers(tgid=22) ⓘ

HER2/EBBR2↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,  
Total Targets: 32

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiArt↑, 1,   diuretic↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

ROS↓, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↝, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

HDAC↓, 1,  

Migration(tgid=13) ⓘ

MMP13↓, 1,   MMP3↓, 1,   PKCδ↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

Hif1a↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2↓, 2,   Inflam↓, 3,   NF-kB↓, 1,   PGE2↓, 1,   TNF-α↓, 1,  

Synaptic & Neurotransmission(tgid=18) ⓘ

tau↓, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AST↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 1,   cardioP↑, 1,   hepatoP↑, 1,   neuroP↑, 1,   toxicity↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,  
Total Targets: 24

Scientific Paper Hit Count for: COX2, cycloocygenase-2 (Cox-2) mRNA and Cox-2 protein
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:75  Target#:66  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page